Investor Presentaiton
For personal use only
Market opportunity for prostate imaging is expanding
Due to growing incidence rates and practice guidelines
Potential clinical utilisation:
1. Primary staging in newly diagnosed high-risk prostate
cancer (NCCN)
2. Biochemical recurrence following prostatectomy or
radiation therapy (NCCN)
3. Monitoring of response to systemic therapy (Future)
4. Patient selection for targeted radio-ligand therapy (Future)
US PATIENTS
(PRIOR)
146,000
US PATIENTS
(REVISED)
194,5101
(1) 57,000
(1) 55,000
(2) 74,000
(2) 52,000
(3) 35,000
(3) 22,000
(4) 17,000
(4) 28,000
US total addressable market (TAM) value
USD $575M
USD $750M
TAM value including EU2
USD $900M
USD $1.08B3
1. American Cancer Society (ACS). Cancer Facts & Figures 2021. Atlanta, GA: American Cancer Society; 2021.
2. EU countries included in MAA submission to Danish Medicines Authority on 30 April 2020.
3. Dollar ($) TAM values are management estimates based on ACS (US) and Globocan (EU) reported incidence x estimated unit cost per dose.
Telix Pharmaceuticals Limited (ASX: TLX)
23
TELIX
PHARMACEUTICALSView entire presentation